CFO of CRISPR (NASDAQ: CRSP) unloads 34,972 shares via plan

Q: What insider transaction did CRISPR Therapeutics (CRSP) report?

CRISPR Therapeutics’ Chief Financial Officer Prasad Raju exercised options for 34,972 Common Shares at $45.15 per share and sold 34,972 shares at a weighted average price of $60.19 on January 22, 2026.

Q: What prices were involved in the CRSP CFO’s option exercise and sale?

The stock option had an exercise price of $45.15 per share. The 34,972 shares sold were transacted at a weighted average price of $60.19 , with individual trade prices ranging from $60.00 to $60.42 .

Q: What are the terms of the CRISPR Therapeutics stock option exercised?

The option was granted on March 14, 2023 for 100,000 Common Shares , with 25% vesting on March 14, 2024 and the remaining shares vesting monthly over the following 36 months .

Q: What role does the reporting person hold at CRISPR Therapeutics (CRSP)?

The reporting person on this Form 4, Prasad Raju , serves as the company’s Chief Financial Officer .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics’ Chief Financial Officer Prasad Raju reported an option exercise and share sale. On January 22, 2026, he exercised a stock option for 34,972 Common Shares at an exercise price of $45.15 per share, acquiring the same number of common shares. That same day, he sold 34,972 Common Shares at a weighted average price of $60.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025. After these transactions, he directly held 6,767 Common Shares and 41,667 stock options.

Insider Trade Summary

Net Seller: 34,972 shares ($2,104,965)

Net Sell 3 txns

Insider Prasad Raju

Role Chief Financial Officer

Sold 34,972 shs ($2.10M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	34,972	$0.00	--
Exercise	Common Shares	34,972	$45.15	$1.58M
Sale	Common Shares	34,972	$60.19	$2.10M

Holdings After Transaction: Stock Option (Right to Buy) — 41,667 shares (Direct); Common Shares — 41,739 shares (Direct)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

01/26/2026 - 05:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prasad Raju

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

02127

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	01/22/2026		M		34,972	A	$45.15	41,739	D
Common Shares	01/22/2026		S⁽¹⁾		34,972	D	$60.19⁽²⁾	6,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$45.15	01/22/2026		M			34,972	⁽³⁾	03/14/2033	Common Shares	34,972	$0.00	41,667	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CRISPR Therapeutics (CRSP) report?

CRISPR Therapeutics’ Chief Financial Officer Prasad Raju exercised options for 34,972 Common Shares at $45.15 per share and sold 34,972 shares at a weighted average price of $60.19 on January 22, 2026.

Was the CRSP CFO’s stock sale under a 10b5-1 trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

How many CRISPR Therapeutics shares does the CFO hold after this Form 4?

Following the reported transactions, the CFO directly owned 6,767 Common Shares and 41,667 stock options of CRISPR Therapeutics.

What prices were involved in the CRSP CFO’s option exercise and sale?

The stock option had an exercise price of $45.15 per share. The 34,972 shares sold were transacted at a weighted average price of $60.19, with individual trade prices ranging from $60.00 to $60.42.

What are the terms of the CRISPR Therapeutics stock option exercised?

The option was granted on March 14, 2023 for 100,000 Common Shares, with 25% vesting on March 14, 2024 and the remaining shares vesting monthly over the following 36 months.

What role does the reporting person hold at CRISPR Therapeutics (CRSP)?

The reporting person on this Form 4, Prasad Raju, serves as the company’s Chief Financial Officer.